Effect of selected antimalarial drugs and inhibitors of cytochrome P- 450 3A4 on halofantrine metabolism by human liver microsomes

Drug Metabolism and Disposition

Volumn 27, Issue 5, 1999, Pages 565-568

  Baune, B ^a   Furlan, V ^b   Taburet, A M ^b   Farinotti, R ^a  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b BICÊTRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMODIAQUINE; ANTIMALARIAL AGENT; ARTEMETHER; ARTEMISININ; CYTOCHROME P450 ISOENZYME; DOXYCYCLINE; HALOFANTRINE; KETOCONAZOLE; MEFLOQUINE; PRIMAQUINE; PROGUANIL; PYRIMETHAMINE; QUINIDINE; QUININE; SULFADOXINE;

ARTICLE; CARDIOTOXICITY; COMPETITIVE INHIBITION; DRUG COMPETITION; DRUG INHIBITION; DRUG METABOLISM; DRUG POTENTIATION; DRUG STRUCTURE; ENZYME ACTIVITY; HUMAN; LIVER MICROSOME; MALARIA FALCIPARUM; PRIORITY JOURNAL;

ADOLESCENT; ADULT; ANTIFUNGAL AGENTS; ANTIMALARIALS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; ENZYME INHIBITORS; HUMANS; KETOCONAZOLE; MALE; MICROSOMES, LIVER; MIDDLE AGED; MIXED FUNCTION OXYGENASES; PHENANTHRENES;

EID: 0032929024     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Andersson T, Miners JO, Veronese ME and Birkett DJ (1994) Diazepam metabolism liver microsomes is mediated by both S-mephenytoin hydroxylase and CYP 3A isoforms. Br J Clin Pharmacol 38:131-137.
2. Bangchang KN, Karbwang J and Back DJ (1992a) Mefloquine metabolism by human liver microsomes: Effect of other antimalarial drugs. Biochem Pharmacol 43:1957-1961.
3. Bangchang KN, Karbwang J and Back DJ (1992b) Primaquine metabolism by human liver microsomes: Effect of other antimalarial drugs. Biochem Pharmacol 44:587-590.
4. Borelli D, Bran JL, Fuentes J, Legendre R, Leiderman E, Levine HB, Restrepo A and Stevens DA (1979) Ketoconazole, an oral antifungal: Laboratory and clinical assessment of imidazole drugs. Postgrad Med J 55:657-661.
5. Boudreau EF, Pang LW, Dixon KE, Webster HK, Pavanand K, Tosingha L, Somutsakorn P and Canfield CJ (1988) Malaria: Treatment efficacy of halofantrine (WR 171,669) in initial field trials in Thailand. Bull WHO 66:227-235.
6. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
7. Campana C, Regazzi MB, Buggia I and Molinaro M (1996) Clinically significant drug interactions with cyclosporine. An update. Clin Pharmacokinet 30:141-179.
8. Castot A, Rapoport P and Le coz P (1993) Prolonged QT interval with halofantrine. Lancet 341:1541.
9. Dragacci S, Thomassin J, Magdalou J, Souhaili El Amri H, Boissel P and Siest G (1987) Properties of human hepatic UDP-glucuronosyltransferases. Relationship to other inducible enzymes in patients with cholestasis. Ear J Clin Pharmacol 32:485-491.
10. Franke U, Proksch B, Muller M, Risler T and Ehninger G (1987) Drug monitoring of quinine by HPLC in cerebral malaria with acute renal failure treated by haemofiltration. Eur J Clin Pharmacol 33:293-296.
11. Funck-Brentano C, Becquemont L, Lenevu A, Roux A, Jaillon P and Beaune P (1997) Inhibition by omeprazole of proguanil metabolism: Mechanism of the interaction in vitro and prediction of in vivo results from the in vitro experiments. J Pharmacol Exp Ther 280:730-738.
12. Gimenez F, Aubry AF, Farinotti R, Kirkland K and Wainer IW (1992) The determination of the enantiomers of halofantrine and monodesbutylhalofantrine in plasma and whole blood using a sequential achiral-chiral high performance liquid chromatography. J Pharm Biomed Anal 10:245-250.
13. Graybill JR, Lundberg D, Donovan W, Levine HB, Rodriguez MD and Drutz DJ (1980) Treatment of coccidioidomycosis with ketoconazole: Clinical and laboratory studies of 18 patients. Rev Infect Dis 2:661-673.
14. Halliday RC, Jones BC, Smith DA, Kitterincham NR and Park BK (1995) An investigation of the interaction between halofantrine, CYP 2D6 and CYP 3A4, studies with human liver microsomes and heterologous enzyme expression systems. Br J Clin Pharmacol 40:369-378.
15. Honig PK, Wortham DC, Zamani K, Conner DP, Mullin JC and Cantilena LR (1993) Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. JAMA 24:1513-1518.
16. Karbwang J and Na Bangchang K (1994) Clinical of halofantrine. Clin Pharmacokinet 27:104-119.
17. Kenworthy KE, Clarke SE, Andrews J and Houston JB (1998) The simultaneous metabolism and binding of testosterone and diazepam in a recombinant CYP 3A4 enzyme system. Presented at 12th International Symposium On Microsomes and Drug Oxidations, 20-24 July, Montpellier, France.
18. Kerr BM, Thummel KE, Wurden CJ, Klein SM, Kroetz DL, Gonzalez FJ and Levy RH (1994) Human liver carbamazepine metabolism: Role of CYP 3A4 and 2C8 in 10,11-epoxide formation. Biochem Pharmacol 47:1969-1979.
19. Khoo S-M, Porter CJH, Edwards GE and Charman WN (1998) Metabolism of halofantrine to its equipotent metabolite, desbutylhalofantrine, is decreased when orally administrated with ketoconazole. J Pharm Sci 87:1538-1541.
20. Koley AP, Robinson RC, Markowitz A and Friedman FK (1997) Drug-drug interactions: Effect of quinidine on nifedipine binding to human cytochrome P450 3A4. Biochem Pharmacol 53:455-460.
21. Li AP, Kaminski DL and Rasmussen A (1995) Substrates of human hepatic cytochrome P450 3A4. Toxicology 104:1-8.
22. Nosten F, Ter Kuile FO, Luxemburger C, Woodrow C, Kyle DE, Chongsuphajaisiddhi T and White NJ (1993) Cardiac effects of antimalarial treatment with halofantrine. Lance: 341: 1054-1056.
23. Panisko DM and Keystone JS (1990) Treatment of malaria-1990. Drugs 39:160-189.
24. Pichard L, Fabre I, Fabre G, Domergue J, Saint Aubert B, Mourad G and Maurel P (1990) Cyclosporine A drug interactions, screening for inducers and inhibitors of cytochrome P450 (cyclosporine A oxidase) in primary cultures of human hepatocytes and liver nucrosomes. Drug Metab Dispos 18:595-606.
25. Pohjola-Sintonen S, Vitasalo M, Toivonen L and Neuvonen P (1993) Torsades de pointes after terfenadine-itraconazole interaction. Br Med J 306:186.
26. Segel IH (1975) Enzyme Kinetics: Behavior and Analysis of Rapid Equilibrium and Steady-State Enzyme Systems. John Wiley & Sons, Inc., New York.
27. White NJ (1985) Clinical pharmacokinetics of antimalarial drugs. Clin Pharmacokinet 10:187-215
28. Zhang H, Coville PF, Walker RJ, Miners JO, Birkett DJ and Wanwimolruk S (1997) Evidence for involvement of human CYP 3A in the 3-hydroxylation of quinine. Br J Clin Pharmacol 43:245-252.
29. Zhao XJ and Ishizaki T (1997) Metabolic interactions of selected antimalarial and non-antimalarial drugs with the major pathway (3-hydroxylation) of quinine in human liver microsomes. Br J Clin Pharmacol 44:505-511.